Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Clinical trial NCT02346032 · COMPLETED
Trial details
- NCT number
- NCT02346032
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-30
- Primary completion
- 2016-09-30
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.